Moderna, Inc. (MRNA)
138.82
-6.31
(-4.35%)
USD |
NASDAQ |
Aug 24, 16:00
139.00
+0.18
(+0.13%)
After-Hours: 20:00
Moderna Enterprise Value : 54.06B for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 54.06B |
| August 20, 2026 | 49.34B |
| August 19, 2026 | 65.73B |
| August 18, 2026 | 21.27B |
| August 17, 2026 | 21.87B |
| August 14, 2026 | 21.41B |
| August 13, 2026 | 21.55B |
| August 12, 2026 | 21.55B |
| August 11, 2026 | 20.32B |
| August 10, 2026 | 20.01B |
| August 07, 2026 | 19.76B |
| August 06, 2026 | 17.64B |
| August 05, 2026 | 18.59B |
| August 04, 2026 | 18.89B |
| August 03, 2026 | 18.15B |
| July 31, 2026 | 18.02B |
| July 30, 2026 | 19.26B |
| July 29, 2026 | 17.89B |
| July 28, 2026 | 18.42B |
| July 27, 2026 | 18.35B |
| July 24, 2026 | 17.72B |
| July 23, 2026 | 18.90B |
| July 22, 2026 | 19.32B |
| July 21, 2026 | 19.95B |
| July 20, 2026 | 19.89B |
| Date | Value |
|---|---|
| July 17, 2026 | 20.82B |
| July 16, 2026 | 21.35B |
| July 15, 2026 | 23.39B |
| July 14, 2026 | 23.06B |
| July 13, 2026 | 22.89B |
| July 10, 2026 | 23.39B |
| July 09, 2026 | 26.70B |
| July 08, 2026 | 25.60B |
| July 07, 2026 | 27.98B |
| July 06, 2026 | 28.79B |
| July 02, 2026 | 27.97B |
| July 01, 2026 | 25.08B |
| June 30, 2026 | 24.09B |
| June 29, 2026 | 23.76B |
| June 26, 2026 | 22.80B |
| June 25, 2026 | 19.81B |
| June 24, 2026 | 20.08B |
| June 23, 2026 | 20.31B |
| June 22, 2026 | 19.65B |
| June 18, 2026 | 21.49B |
| June 17, 2026 | 20.63B |
| June 16, 2026 | 18.09B |
| June 15, 2026 | 16.79B |
| June 12, 2026 | 15.91B |
| June 11, 2026 | 15.80B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| BioNTech SE | 12.75B |
| Kailera Therapeutics, Inc. | 1.319B |
| Sarepta Therapeutics, Inc. | 2.242B |
| Replimune Group, Inc. | 1.157B |
| Intellia Therapeutics, Inc. | 1.433B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -782.00M |
| Revenue (Quarterly) | 145.00M |
| Total Expenses (Quarterly) | 927.00M |
| EPS Diluted (Quarterly) | -1.965 |
| Gross Profit Margin (Quarterly) | -7.59% |
| Profit Margin (Quarterly) | -539.3% |
| Earnings Yield | -5.75% |
| Normalized Earnings Yield | -5.752 |